Mary Wilson
Well-known member
Author manuscript; available in PMC 2019 May 1
doi: 10.1016/j.antiviral.2018.11.004
Brett W. Petersen,[SUP]a,[/SUP][SUP]*,[/SUP][SUP]1[/SUP] Joelle Kabamba,[SUP]b,[/SUP][SUP]1[/SUP] Andrea M. McCollum,[SUP]a[/SUP]Robert Shongo Lushima,[SUP]c[/SUP] Emile Okitolonda Wemakoy,[SUP]d[/SUP]Jean-Jacques Muyembe Tamfum,[SUP]e[/SUP] Beatrice Nguete,[SUP]d[/SUP]Christine M. Hughes,[SUP]a[/SUP] Benjamin P. Monroe,[SUP]a[/SUP] and Mary G. Reynolds[SUP]a[/SUP]
Abstract
Healthcare-associated transmission of monkeypox has been observed on multiple occasions in areas where the disease is endemic. Data collected by the US Centers for Disease Control and Prevention (CDC) from an ongoing CDC-supported program of enhanced surveillance in the Tshuapa Province of the Democratic Republic of the Congo, where the annual incidence of human monkeypox is estimated to be 3.5–5/10,000, suggests that there is approximately one healthcare worker infection for every 100 confirmed monkeypox cases. Herein, we describe a study that commenced in February 2017, the intent of which is to evaluate the effectiveness, immunogenicity, and safety of a third-generation smallpox vaccine, IMVAMUNE®, in healthcare personnel at risk of monkeypox virus (MPXV) infection. We describe procedures for documenting exposures to monkeypox virus infection in study participants, and outline lessons learned that may be of relevance for studies of other investigational medical countermeasures in hard to reach, under-resourced populations.
1. Introduction
It is estimated that more than 1000 cases of human monkeypox (MPX) occur in the Democratic Republic of the Congo (DRC) each year, leading to frequent exposures of healthcare workers (HCWs) to the disease. In this paper, we describe a collaboration among the U.S. Centers for Disease Control and Prevention (CDC), the DRC Ministry of Health (MOH), and the Kinshasa School of Public Health (KSPH), to perform a vaccine study in adult HCWs in Tshuapa, DRC to evaluate the effectiveness of the attenuated smallpox vaccine, IMVAMUNE®, to prevent infection with monkeypox virus (MPXV). ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438175/
doi: 10.1016/j.antiviral.2018.11.004
Brett W. Petersen,[SUP]a,[/SUP][SUP]*,[/SUP][SUP]1[/SUP] Joelle Kabamba,[SUP]b,[/SUP][SUP]1[/SUP] Andrea M. McCollum,[SUP]a[/SUP]Robert Shongo Lushima,[SUP]c[/SUP] Emile Okitolonda Wemakoy,[SUP]d[/SUP]Jean-Jacques Muyembe Tamfum,[SUP]e[/SUP] Beatrice Nguete,[SUP]d[/SUP]Christine M. Hughes,[SUP]a[/SUP] Benjamin P. Monroe,[SUP]a[/SUP] and Mary G. Reynolds[SUP]a[/SUP]
Abstract
Healthcare-associated transmission of monkeypox has been observed on multiple occasions in areas where the disease is endemic. Data collected by the US Centers for Disease Control and Prevention (CDC) from an ongoing CDC-supported program of enhanced surveillance in the Tshuapa Province of the Democratic Republic of the Congo, where the annual incidence of human monkeypox is estimated to be 3.5–5/10,000, suggests that there is approximately one healthcare worker infection for every 100 confirmed monkeypox cases. Herein, we describe a study that commenced in February 2017, the intent of which is to evaluate the effectiveness, immunogenicity, and safety of a third-generation smallpox vaccine, IMVAMUNE®, in healthcare personnel at risk of monkeypox virus (MPXV) infection. We describe procedures for documenting exposures to monkeypox virus infection in study participants, and outline lessons learned that may be of relevance for studies of other investigational medical countermeasures in hard to reach, under-resourced populations.
1. Introduction
It is estimated that more than 1000 cases of human monkeypox (MPX) occur in the Democratic Republic of the Congo (DRC) each year, leading to frequent exposures of healthcare workers (HCWs) to the disease. In this paper, we describe a collaboration among the U.S. Centers for Disease Control and Prevention (CDC), the DRC Ministry of Health (MOH), and the Kinshasa School of Public Health (KSPH), to perform a vaccine study in adult HCWs in Tshuapa, DRC to evaluate the effectiveness of the attenuated smallpox vaccine, IMVAMUNE®, to prevent infection with monkeypox virus (MPXV). ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438175/